MSCI Equity Indexes May 2019 Index Review
LONDON–(BUSINESS WIRE)–MSCI Inc. (NYSE:MSCI), a leading provider of research-based indexes and
analytics, announced the results of the May 2019 Semi-Annual Index
Review for the MSCI Equity Indexes – including the MSCI Global Standard,
MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Global Value
and Growth Indexes, the MSCI Frontier Markets, and MSCI Frontier Markets
Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small
Cap Indexes, the MSCI Pan-Euro and MSCI Euro Indexes, the MSCI US Equity
Indexes, the MSCI US REIT Index, the MSCI China A Indexes, MSCI China A
Onshore Indexes and the MSCI China All Shares Indexes. All changes will
be implemented as of the close of May 28, 2019. These changes have been
posted on the Index Review web page on MSCI’s web site at https://www.msci.com/index-review.
Inclusion of the MSCI Saudi Arabia Indexes in Emerging Markets:
Coinciding with this Index Review, MSCI will implement the first step of
the inclusion of the MSCI Saudi Arabia Indexes in the MSCI Emerging
Markets Indexes. Thirty Saudi Arabian securities will be added at half
of their FIF1-adjusted market capitalization, representing an
aggregate weight of 1.42% in the MSCI Emerging Markets Index. The second
and final step of the inclusion will coincide with the August 2019
Quarterly Index Review.
Inclusion of the MSCI Argentina Indexes in Emerging Markets: MSCI
will reclassify the MSCI Argentina Indexes from Frontier Markets to
Emerging Markets in one step coinciding with this Index Review. Eight
Argentinian securities will be added at an aggregate weight of 0.26% in
the MSCI Emerging Markets Index.
Weight Increase of China A Shares in Emerging Markets: MSCI will
implement the first step of the weight increase of China A shares in the
MSCI Emerging Markets Indexes. Twenty-six China A shares (18 of which
are ChiNext stocks) will be added to the MSCI China Index and the
inclusion factor for 238 existing constituents will be increased from
0.05 to 0.10. China A shares will have an aggregate weight of 5.25% and
1.76% in the MSCI China and MSCI Emerging Markets Indexes, respectively.
As a reminder, the weight increase of China A shares in the MSCI
Emerging Markets Indexes will be implemented through a three-step
process. The FIF-adjusted market capitalization of China A shares will
be further increased to 0.15 as part of the August 2019 Quarterly Index
Review and then to 0.20, together with the inclusion of Mid Cap China A
shares, in the final step as part of the November 2019 Semi-Annual Index
Review.
MSCI has published the list of constituents of the MSCI Saudi Arabia,
MSCI Argentina and MSCI China A Indexes to reflect the results of the
May 2019 Semi-Annual Index Review at https://www.msci.com/market-classification.
In addition, MSCI has updated the list of China A Mid Cap securities
that may potentially be added to the MSCI China and the MSCI Emerging
Markets Indexes as part of the third step of the weight increase to be
implemented at the November 2019 Semi-Annual Index Review.
MSCI Global Standard Indexes: One hundred twenty-two securities
will be added to and 41 securities will be deleted from the MSCI ACWI
Index. In the MSCI World Index, the three largest additions measured by
full company market capitalization will be Knorr-Bremse (Germany), Snap
A (USA) and Twilio A (USA). The three largest additions to the MSCI
Emerging Markets Index measured by full company market capitalization
will be Saudi Basic Industries Corporation (Saudi Arabia), Saudi Telecom
Company (Saudi Arabia) and Al Rajhi Banking and Investment Corporation
(Saudi Arabia).
MSCI Global Small Cap Indexes: There will be 344 additions to and
195 deletions from the MSCI ACWI Small Cap Index.
MSCI Global Investable Market Indexes: There will be 400
additions to and 170 deletions from the MSCI ACWI Investable Market
Index (IMI).
MSCI Global All Cap Indexes: There will be 350 additions to and
148 deletions from the MSCI World All Cap Index.
MSCI Frontier Markets Indexes: There will be two additions to and
23 deletions from the MSCI Frontier Markets Index. The two additions to
the MSCI Frontier Markets Index will be Petrovietnam Power (Vietnam) and
Banque De Tunisie (Tunisia). There will be 12 additions to and 24
deletions from the MSCI Frontier Markets Small Cap Index.
MSCI will launch the MSCI Malta Investable Market Index as a Standalone
Index as part of the May 2019 Semi-Annual Index Review. The index will
initially include one Standard Size-Segment constituent and two Small
Cap Size-Segment constituents.
MSCI Global Islamic Indexes: Seventy-one securities will be added
to and 49 securities will be deleted from the MSCI ACWI Islamic Index.
The three largest additions to the MSCI ACWI Islamic Index measured by
full company market capitalization will be Abbott Laboratories (USA),
Saudi Basic Industries Corporation (Saudi Arabia) and Linde (New) (USA).
There will be no additions to and two deletions from the MSCI Gulf
Cooperation Council (GCC) Countries ex Saudi Arabia IMI Islamic Index.
MSCI US Equity Indexes: There will be seven securities added to
and four securities deleted from the MSCI US Large Cap 300 Index. The
three largest additions to the MSCI US Large Cap 300 Index measured by
full company market capitalization will be Xilinx, Arista Networks and
Transdigm Group Inc.
Thirty-one securities will be added to and 20 securities will be deleted
from the MSCI US Mid Cap 450 Index. The three largest additions to the
MSCI US Mid Cap 450 Index measured by full company market capitalization
will be Omnicom Group, Altice USA A and Apache Corporation.
One hundred fifty securities will be added to and 62 securities will be
deleted from the MSCI US Small Cap 1750 Index. The three largest
additions to the MSCI US Small Cap 1750 Index measured by full company
market capitalization will be Smartsheet A, ADT and Avnet.
There will be 49 additions to and 30 deletions from the MSCI US Micro
Cap Index.
For the MSCI US Investable Market Value Index, there will be 149
additions or upward changes in Value Inclusion Factor (VIFs), and 126
deletions or downward changes in VIFs. For the MSCI US Investable Market
Growth Index, there will be 196 additions or upward changes in Growth
Inclusion Factors (GIFs), and 128 deletions or downward changes in GIFs.
MSCI US REIT Index: There will be one addition to and two
deletions from the MSCI US REIT Index. The addition to the MSCI US REIT
Index will be Innovative Industrial Properties, Inc.
MSCI China A Indexes: There will be 26 additions to and no
deletions from the MSCI China A Large Cap Index resulting in 264 index
constituents. There will be 29 additions to and five deletions from the
MSCI China A Mid Cap Index resulting in 173 index constituents.
MSCI China A Onshore Indexes: There will be 109 additions to and
three deletions from the MSCI China A Onshore Index. The three largest
additions to the MSCI China A Onshore Index will be Wens Foodstuff Group
A, Contemporary A and Shenzhen Mindray A. There will be 503 additions to
and 49 deletions from the MSCI China A Onshore Small Cap Index. Most of
the additions are newly eligible ChiNext stocks.
MSCI China All Shares Indexes: There will be 66 additions to and
10 deletions from the MSCI China All Shares Index. The three largest
additions to the MSCI China All Shares Index will be Wens Foodstuff
Group A, Contemporary A and Shenzhen Mindray A. There will be 522
additions to and 46 deletions from the MSCI China All Shares Small Cap
Index. Most of the additions are newly eligible ChiNext stocks.
-Ends-
About MSCI
MSCI is a leading provider of critical decision support tools and
services for the global investment community. With over 45 years of
expertise in research, data and technology, we power better investment
decisions by enabling clients to understand and analyze key drivers of
risk and return and confidently build more effective portfolios. We
create industry-leading research-enhanced solutions that clients use to
gain insight into and improve transparency across the investment
process. To learn more, please visit www.msci.com.
This document and all of the information contained in it, including
without limitation all text, data, graphs, charts (collectively, the
“Information”) is the property of MSCI Inc. or its subsidiaries
(collectively, “MSCI”), or MSCI’s licensors, direct or indirect
suppliers or any third party involved in making or compiling any
Information (collectively, with MSCI, the “Information Providers”) and
is provided for informational purposes only. The Information may not be
modified, reverse-engineered, reproduced or redisseminated in whole or
in part without prior written permission from MSCI.
The Information may not be used to create derivative works or to verify
or correct other data or information. For example (but without
limitation), the Information may not be used to create indexes,
databases, risk models, analytics, software, or in connection with the
issuing, offering, sponsoring, managing or marketing of any securities,
portfolios, financial products or other investment vehicles utilizing or
based on, linked to, tracking or otherwise derived from the Information
or any other MSCI data, information, products or services.
The user of the Information assumes the entire risk of any use it may
make or permit to be made of the Information. NONE OF THE INFORMATION
PROVIDERS MAKES ANY EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS
WITH RESPECT TO THE INFORMATION (OR THE RESULTS TO BE OBTAINED BY THE
USE THEREOF), AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW,
EACH INFORMATION PROVIDER EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES
(INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF ORIGINALITY,
ACCURACY, TIMELINESS, NON-INFRINGEMENT, COMPLETENESS, MERCHANTABILITY
AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO ANY OF THE
INFORMATION.
Without limiting any of the foregoing and to the maximum extent
permitted by applicable law, in no event shall any Information Provider
have any liability regarding any of the Information for any direct,
indirect, special, punitive, consequential (including lost profits) or
any other damages even if notified of the possibility of such damages.
The foregoing shall not exclude or limit any liability that may not by
applicable law be excluded or limited, including without limitation (as
applicable), any liability for death or personal injury to the extent
that such injury results from the negligence or willful default of
itself, its servants, agents or sub-contractors.
Information containing any historical information, data or analysis
should not be taken as an indication or guarantee of any future
performance, analysis, forecast or prediction. Past performance does not
guarantee future results.
The Information should not be relied on and is not a substitute for the
skill, judgment and experience of the user, its management, employees,
advisors and/or clients when making investment and other business
decisions. All Information is impersonal and not tailored to the needs
of any person, entity or group of persons.
None of the Information constitutes an offer to sell (or a solicitation
of an offer to buy), any security, financial product or other investment
vehicle or any trading strategy.
It is not possible to invest directly in an index. Exposure to an asset
class or trading strategy or other category represented by an index is
only available through third party investable instruments (if any) based
on that index. MSCI does not issue, sponsor, endorse, market, offer,
review or otherwise express any opinion regarding any fund, ETF,
derivative or other security, investment, financial product or trading
strategy that is based on, linked to or seeks to provide an investment
return related to the performance of any MSCI index (collectively,
“Index Linked Investments”). MSCI makes no assurance that any Index
Linked Investments will accurately track index performance or provide
positive investment returns. MSCI Inc. is not an investment adviser or
fiduciary and MSCI makes no representation regarding the advisability of
investing in any Index Linked Investments.
Index returns do not represent the results of actual trading of
investible assets/securities. MSCI maintains and calculates indexes, but
does not manage actual assets. Index returns do not reflect payment of
any sales charges or fees an investor may pay to purchase the securities
underlying the index or Index Linked Investments. The imposition of
these fees and charges would cause the performance of an Index Linked
Investment to be different than the MSCI index performance.
The Information may contain back tested data. Back-tested performance is
not actual performance, but is hypothetical. There are frequently
material differences between back tested performance results and actual
results subsequently achieved by any investment strategy.
Constituents of MSCI equity indexes are listed companies, which are
included in or excluded from the indexes according to the application of
the relevant index methodologies. Accordingly, constituents in MSCI
equity indexes may include MSCI Inc., clients of MSCI or suppliers to
MSCI. Inclusion of a security within an MSCI index is not a
recommendation by MSCI to buy, sell, or hold such security, nor is it
considered to be investment advice.
Data and information produced by various affiliates of MSCI Inc.,
including MSCI ESG Research LLC and Barra LLC, may be used in
calculating certain MSCI indexes. More information can be found in the
relevant index methodologies on www.msci.com.
MSCI receives compensation in connection with licensing its indexes to
third parties. MSCI Inc.’s revenue includes fees based on assets in
Index Linked Investments. Information can be found in MSCI Inc.’s
company filings on the Investor Relations section of www.msci.com.
MSCI ESG Research LLC is a Registered Investment Adviser under the
Investment Advisers Act of 1940 and a subsidiary of MSCI Inc. Except
with respect to any applicable products or services from MSCI ESG
Research, neither MSCI nor any of its products or services recommends,
endorses, approves or otherwise expresses any opinion regarding any
issuer, securities, financial products or instruments or trading
strategies and MSCI’s products or services are not intended to
constitute investment advice or a recommendation to make (or refrain
from making) any kind of investment decision and may not be relied on as
such. Issuers mentioned or included in any MSCI ESG Research materials
may include MSCI Inc., clients of MSCI or suppliers to MSCI, and may
also purchase research or other products or services from MSCI ESG
Research. MSCI ESG Research materials, including materials utilized in
any MSCI ESG Indexes or other products, have not been submitted to, nor
received approval from, the United States Securities and Exchange
Commission or any other regulatory body.
Any use of or access to products, services or information of MSCI
requires a license from MSCI. MSCI, Barra, RiskMetrics, IPD and other
MSCI brands and product names are the trademarks, service marks, or
registered trademarks of MSCI or its subsidiaries in the United States
and other jurisdictions. The Global Industry Classification Standard
(GICS) was developed by and is the exclusive property of MSCI and
Standard & Poor’s. “Global Industry Classification Standard (GICS)” is a
service mark of MSCI and Standard & Poor’s.
MIFID2/MIFIR notice: MSCI ESG Research LLC does not distribute or act as
an intermediary for financial instruments or structured deposits, nor
does it deal on its own account, provide execution services for others
or manage client accounts. No MSCI ESG Research product or service
supports, promotes or is intended to support or promote any such
activity. MSCI ESG Research is an independent provider of ESG data,
reports and ratings based on published methodologies and available to
clients on a subscription basis. We do not provide custom or one-off
ratings or recommendations of securities or other financial instruments
upon request.
Privacy notice: For information about how MSCI ESG Research LLC collects
and uses personal data concerning officers and directors, please refer
to our Privacy Notice at https://www.msci.com/privacy-pledge.
1 Foreign Inclusion Factor
Contacts
Media Inquiries
[email protected]
Sam
Wang +1 212 804 5244
Melanie Blanco +1 212 981 1049
Laura
Hudson +44 20 7336 9653
MSCI Global Client Service
EMEA
Client Service + 44 20 7618.2222
Americas Client Service +1 888 588
4567 (toll free)
Asia Pacific Client Service + 852 2844 9333
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the “Units”) at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the “Offering”).
Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); and (ii) one (1) common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.32 for a period of four (4) years from the date of issuance.
Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.
The securities issued to Canadian subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Iris Bincovich, Chief Executive Officer of the Company, stated “we are very pleased with our successful offering. I would like to extend my sincere gratitude to our investors for their unwavering support. We see this as a strong vote of confidence by both existing and new investors which demonstrates investor support of our vision and strategic direction. These new funds will provide us with additional working capital to enable us to capitalize on new opportunities and allow us to advance strongly on our growth plans.”
The Company is also pleased to announce that it has granted an aggregate of 300,000 stock options (each an “Option“) to certain consultants of the Company pursuant to the Company’s stock option plan (the “Plan“). Each Option may be exercised for one (1) common share in the capital of the Company (each, a “Share“) at a price of $0.25 per Share. The Options expire on August 27, 2029.
All Options granted vest in accordance with the following vesting schedule: (i) 1/3rd of the Options vested immediately at grant; (ii) 1/3rd of the Options will vest on February 28, 2025; and (iii) 1/3rd will vest on August 27, 2025; all subject to the terms and conditions of the Plan.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Logo – https://mma.prnewswire.com/media/2046271/4883982/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options-302234455.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Cannabis2 weeks agoSilly Nice Announces Launch of New 1G 510 Vape Cartridge and 2G All-In-One Vape in New York Dispensaries This September
-
Cannabis2 weeks agoCannabis Cultivation Market – Global Food Additives, Oils, Tinctures, Cannabis Indica, Cannabis Sativa Forecast 2024-2030
-
Cannabis1 week ago
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
-
Cannabis2 weeks ago
Global Hemp Based Food Market Size To Worth USD 4.87 Billion By 2033 | CAGR Of 13.12%
-
Innocan1 week agoInnocan Pharma Announces Closing of Private Placement and Grant of Stock Options
-
Indivior4 days agoIndivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
